다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Neurocrine Biosciences Inc (NBIX)
Neurocrine Biosciences Inc (NBIX) 뉴스

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/03	21:01	PR Newswire (US)	Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/06/03	20:35	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/06/03	20:30	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/31	05:38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/30	05:53	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/30	05:01	PR Newswire (US)	Neurocrine Biosciences to Participate at Investor Conferences in June	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/29	05:14	PR Newswire (US)	Neurocrine Biosciences Announces CEO Succession Plan	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/28	21:30	PR Newswire (US)	Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:34	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	07:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	06:59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/24	05:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06:35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06:27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06:15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	06:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05:51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05:46	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/22	05:05	PR Newswire (US)	Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05:32	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05:31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/18	05:31	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc
2024/05/17	05:55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NBIX	Neurocrine Biosciences Inc

검색 관련기사 보기:NASDAQ:NBIX

1 2 3 4 5 6 7 8 9 10 다음 >>

Deutsche Telekom (QX)

BNP Paribas (QX)

American Express

US Dollar vs Sterling

Financial Select Sector

US Dollar vs Yen

Gold vs US Dollar

US Dollar vs Euro

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관